Goldman SachsGSBUYJan 17, 2024Stock price when the opinion was issued
As of Jul 21, 2026. Market Open.
Different businesses. LLY is a big play in GLP-1 drugs. How will pills effect the injections business? LLY has done a good job of navigating these new pills. GS enjoys increased stock market and IPO businesses. He prefers LLY, which is tied to a secular growth trend, but GS' good times in capturing revenue in this cycle will end.
Mergers are increasing, and banks like GS makes advisory fees from them. Also, the banks have been rallying since oil slumped, and will benefit further from rising interest rates, which appears will happen later this year. Plus, hyperscalers may need to keep borrowing money to keep competing with each other.
Yesterday, they reported a strong EOS beat, up 65% YOY, and new revenues up 7% YOY. Global markets, including investment banking, was lacklustre. Their real driver of growth was asset and wealth management which saw 23% new revenues growth. Meanwhile, it reduced staff to manage costs, but return on equity disappointed. Bottom line: after things settle, more upside lies ahead.